Skip to main content

Industry News

  • Kraft Heinz Company's Indian affiliate Kraft Heinz India which is a food and beverage major With  partnership with Stop Hunger Now, a non-profit organisation, and Society for Action in Community has launched a mobile medical unit (MMU) service in Kalajore village in Bihar, the company release stated.

  • The Indian Patent Office has rejected American drug maker Pfizer's patents for its rheumatoid arthritis drug tofacitinib in India.

    “After having considered the submissions submitted by the applicant (Pfizer) in the hearing, the written submission and amended claims filed as well as in view of the discussions and findings by me, it is hereby ordered that the invention disclosed and claimed in the instant application is not considered as an invention under the provisions of the Act”, said Bharat N S, assistant controller of patents & designs, Mumbai.

  • (Business Wire India); RWL Healthworld Ltd. (formerly known as Religare Wellness) has been re-branded as Fortis Health World; and is successfully running a leading e-commerce portal that sells beauty, wellness and health-care products such as baby care products, face and skin care range, home and living utilities as well as diabetic remedies.

  • Mumbai based pharma major Lupin Limited announced that its subsidiary Lupin Pharmaceuticals Inc (Lupin) has launched its Duloxetine 40 mg delayed-release (DR) capsule, which is the first and only generic Duloxetine formulation to become available in 40 mg dosage strength.

  • Teva Pharmaceutical Industries Ltd launch Zecuity, the first and only patch system in US designed to provide relief from migraine.  Zecuity is a single-use, disposable patch system that delivers sumatriptan through the skin. Zecuity is a prescription medicine used for the acute treatment of migraine headaches with or without aura in adults.

  • Sandoz, a Novartis company and a global leader in generic pharmaceuticals launch of first biosimilar Zarxio (filgrastim-sndz). Zarxio is the first biosimilar approved by the US Food and Drug Administration (FDA).

  • Amgen, a biopharmaceutical company, has entered a neuroscience collaboration with Novartis in the areas of Alzheimer's disease and migraine. The collaboration also enables Amgen to focus on the commercialisation of its migraine programmes in the US, Canada and Japan, while leveraging Novartis' strong commercial capabilities in neuroscience throughout Europe and other markets worldwide.

Subscribe to Industry News